At a glance
The selected source concerns a different, albumin-binding GHRF analogue in cells and rats. No direct study of these exact supplier-labelled materials was verified for this entry.
Identity & scope
Both catalogue aliases explicitly say no DAC. The supplied label alone does not fully document sequence, modifications or formulation. We do not silently equate this material with the albumin-binding analogue.
What the research shows
- The related paper explains why an albumin-binding modification changes persistence and why it matters when reading CJC literature.
Critical interpretation
The missing modification changes the identity question
The FDA chemistry review treats CJC-1295 and CJC-1295 DAC as distinct active moieties and lists salt forms separately. That is a concrete reason to resist treating no DAC as a minor wording difference. Its 2024 review did not identify human studies of the specified no-DAC free base or acetate. This is a dated evidence finding, not proof that no later research exists or a current regulatory conclusion. [2]
Why the related rat paper remains background
The Jetté experiment deliberately joined GHRF-derived molecules to albumin to extend persistence, then measured activity in pituitary cells and rats. Removing that design feature removes a central reason for citing the prolonged exposure. The paper can explain the development programme, but cannot provide the half-life or outcomes of a no-DAC material. For a literature search to become directly applicable, its molecular specification must first match the material under discussion. [1]
Limitations & uncertainties
- The cited preclinical results cannot establish no-DAC pharmacokinetics, human outcomes or nasal absorption.
- A similar compound name is insufficient evidence of molecular equivalence.
Open research questions
- What exact sequence, terminal groups and chemical form does no DAC identify here?
- Is there a primary experiment on that precise molecule and the intended research model?
Selected papers & source records
Download bibliography1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (opens in a new tab)
Jetté L, Léger R, Thibaudeau K, et al. (2005). Endocrinology. DOI: 10.1210/en.2004-1286 (opens in a new tab) · PMID 15817669
- Design & population
- Chemical synthesis, cultured rat pituitary-cell assays and pharmacokinetic experiments in male rats.
- What the study found
- Albumin-binding hGRF analogues retained activity in cells. The selected CJC-1295 analogue stimulated rat GH secretion and remained detectable beyond 72 hours.
- Limits on interpretation
- This work concerns an albumin-binding analogue. It does not test a no-DAC catalogue product or show muscle or strength benefits in people.
2. FDA Evaluation of CJC-1295-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee briefing document (opens in a new tab)
U.S. Food and Drug Administration. (2024). FDA briefing document, December 4, 2024 meeting.
- Design & population
- Official evaluation of five named CJC-1295-related substances, including chemical identity and the scope of identified clinical evidence. Relevant chemistry and clinical-evidence sections were consulted.
- What the study found
- The document distinguishes the no-DAC and DAC active moieties and separate salt forms. FDA did not identify human studies of the specified no-DAC free base or acetate in its review.
- Limits on interpretation
- A dated government evidence and identity review, not an intervention trial or a current legal-status determination. It does not authenticate any supplier material.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.
Selected primary background research plus an explicitly labelled FDA identity/evidence review; no direct trial of the exact supplier-labelled no-DAC material was verified.
Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial
- site.fda.gov CJC-1295 without DAC tetrasubstituted GHRH 2024 chemistry review
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. CJC-1295 (no DAC): literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/cjc-1295-no-dac.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.